News | November 11, 2014

Zilver PTX Drug-Eluting Stent Study Data Show Continued Patency at Five Years

Simultaneous studies in the United States and Japan indicated favorable results for patients with peripheral arterial disease

November 11, 2014 — Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated with Zilver PTX.

The results were presented by Michael Dake, M.D., of Stanford University, at the 2014 Vascular Interventional Advances (VIVA) meeting.

Data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease showed five-year primary patency of 66.4 percent in the superficial femoral artery (SFA) for patients treated with Cook’s paclitaxel-eluting stent. This compares to 43.4 percent patency for patients with balloon angioplasty or provisional bare metal stent placement.

“At five years, Zilver PTX demonstrated a 48 percent reduction in reintervention and a 41 percent reduction in restenosis compared to standard care,” Dake told the VIVA audience. “Five-year data for Zilver PTX versus bare metal stenting confirm a sustained benefit for the paclitaxel-eluting stent. Zilver PTX continues to show benefit through five years with no late catch-up.”

The Zilver PTX Randomized Trial of Paclitaxel-Eluting Stents for Femoropoliteal Artery Disease was a 479-patient multicenter, prospective, randomized study. It was designed to evaluate the PTX stent as a treatment for PAD in the SFA.

One-year post-market surveillance (PMS) study data from Japanese patients who received the Zilver PTX drug-eluting stent confirmed the benefits of the device at 12 months, researchers announced. Japanese researchers presented the PMS study results at the VIVA meeting in Las Vegas. This was the first time the study has been presented in the United States.

The PMS study was based in Japan and presented at VIVA by Hiroyoshi Yokoi, M.D., of Fukuoka Sanno Hospital. It included 907 patients with PAD treated at 95 institutions with Zilver PTX. Of those, 802 were eligible for 12-month follow up. After one year, 91.4 percent of the patients in the follow-up group did not need target lesion revascularization (TLR) of the SFA. The 84.8 percent primary patency result in the PMS study is similar to results from earlier Zilver PTX studies.

The patients studied were real-world cases, many of whom had more severe peripheral arterial disease than patients in the randomized control trial (RCT) for Zilver PTX.

“Many of the Japanese PMS patients’ lesions were more complex, with longer stenosed segments, more in-stent restenosis and fewer patent runoff vessels, compared to the RCT patient cohort,” Yokoi said. “Yet the results were quite favorable even in the more complex lesion sub-group.” Complex lesion sub-group results at 12 months showed 88.3 percent freedom from TLR and 81 percent primary patency.

Zilver PTX is the only drug-eluting stent approved in Japan for treating PAD. It has been approved for use in the European Union since August 2009 and the United States and Japan since 2012. Since its release, the stent has been used to treat more than 25,000 patients in North America, Europe, Asia, South America, Australia and New Zealand.

For more information: www.cookmedical.com

 

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init